Curve Therapeutics Co-Founder and CSO Professor Ali Tavassoli awarded the Royal Society of Chemistry’s Interdisciplinary Prize

Awarded in recognition of excellence in research and innovation and contribution to scientific progress Reflects the revolutionary potential of Curve’s gene-encoded Microcycle® platform to unlock the therapeutic potential of intracellular targets Southampton, UK, 25 June 2025 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company building a pipeline of innovative cyclic peptide and […]

Read more

From big pharma to biotech; reflections on the UK life sciences industry amid British Science Week

Curve Perspectives article – Rab Prinjha Rab Prinjha joined Curve Therapeutics in 2024 as Chief R&D Officer, after 25 years at GSK. In this Curve Perspectives article to mark British Science Week, Rab explains why he joined Curve, how Southampton is shaping up as a biotech hub, and the importance of collaboration in the UK […]

Read more

How Curve’s Proprietary Microcycle® Discovery Platform is Reinventing Drug Discovery

Curve Perspectives article – Ali Tavassoli With its powerful Microcycle platform technology, Curve Therapeutics is building a pipeline of innovative drugs with a focus on cancer, immunology and inflammation. Our Co-Founder and Chief Scientific Officer, Ali Tavassoli, explains more. Simon Kerry and I co-founded Curve in 2019 with a vision to transform the lives of […]

Read more

2024 a transformational year of progress: A note from the CEO

2024 has been a transformational year for Curve.  We kicked off the year with a significant  Series A financing, raising £40.5 million from a world class syndicate which includes our existing blue chip investors Advent Life Sciences and Epidarex Capital, alongside new investment from Pfizer Ventures, Columbus Venture Partners and British Patient Capital. The financing […]

Read more

Curve Therapeutics continues to enhance leadership team with appointment of Rab Prinjha as Chief R&D Officer

Southampton, UK, 9 October 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the appointment of Rab Prinjha, PhD, as Chief Research and Development (R&D) Officer. This continues Curve’s strong momentum expanding its leadership team following the recent appointments of Andre Hoekema and Cora Griffin, joining as Chair of the Board and Head of Business Development respectively.

Read more

Curve Therapeutics further strengthens leadership team with the appointment of Andre Hoekema as new Chair of Board

Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the further strengthening of its leadership team with the appointments of Andre Hoekema as Chair of the Board and Cora Griffin as Head of Business Development.

Read more

Curve Therapeutics strengthens Leadership Team with appointment of experienced biotech executive Simon Jones

Accomplished CFO and COO with proven track record in the biotech and pharmaceutical industry Strengthens Curve’s Leadership Team following £40.5 million Series A financing Southampton, UK, 9 July 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the […]

Read more

Research published in Journal of the American Chemical Society highlights potential of HIF Inhibition as a therapeutic approach for cancers

Research led by Curve CSO Professor Ali Tavassoli’s laboratory at University of Southampton Landmark paper on dual HIF-1 and HIF-2 inhibitor that works by inhibiting the interaction of both HIF-1α and HIF-2α with HIF-1β Southampton, UK, 26 March 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening […]

Read more

Curve Therapeutics April 2024 Conference Attendance

Southampton, UK, 21 March 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces activity at the following scientific and investor conferences during April 2024. Anglonordic Life Science Conference, London, United Kingdom 18 April 2024 Attending: Simon Kerry, Chief […]

Read more

Curve Therapeutics raises £40.5 million to turbocharge discovery platform and advance breakthrough pipeline

Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the close of its successful £40.5 million Series A financing. Pfizer Ventures led the round with participation from Columbus Venture Partners and British Patient Capital, which join founding investor Advent Life Sciences and co-lead from the seed round, Epidarex Capital.

Read more